<DOC>
	<DOCNO>NCT01325935</DOCNO>
	<brief_summary>A prospective multicenter registry real-world Japanese patient undergoing DAPT three month stenting . To assess long-term safety Endeavor Zotarolimus-eluting stent noninferiority primary endpoint two different continuous regimen ( three twelve month ) group DAPT stenting Endeavor Zotarolimus-eluting stent real-world Japanese patient examine optimal duration DAPT stenting Endeavor Zotarolimus-eluting stent . The long-term DAPT group present clinical study ( appropriate post-marketing surveillance Endeavor ) consist consecutive patient undergo DAPT twelve month stenting , short-term DAPT group ( newly register present clinical study ) consist patient instruct undergo DAPT three month stenting .</brief_summary>
	<brief_title>Optimal Duration DAPT Following Treatment With Endeavor ( Zotarolimus-eluting Stent ) Real-world Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>1 . Clinical inclusion criterion Patient age 20 year . Patient clinically indicate PCI stenting least one coronary lesion visually confirm coronary angiography . Patient agree condition receive explanation content present clinical study sign consent form approve ethical review board study site . Patient agree undergo clinical FUs list present protocol . 2 . Coronary angiographic inclusion criterion : Patient &gt; 50 % occlusion stenosis visually confirm coronary angiography native coronary artery &gt; 2.5 mm diameter relevant coronary artery anatomical structure eligible PCI Endeavor Zotarolimuseluting stent . 1 . Clinical exclusion criterion Patient age 85 year . Patient ST elevation MI require primary rescue PCI whose performance status fall exclusion criterion . Patient cardiogenic shock . Patient underwent stent treatment BMS lesion within 6 month prior conduct index PCI target vessel . Patient undergone treatment DES coronary lesion . Patient schedule undergo elective surgery within 12 month index PCI . Patient whose leave ventricular ejection fraction ( LVEF ) &lt; 40 % . Patient hemorrhagic predisposition history coagulation abnormality Patient total number deploy stent exceed 4 , regardless number lesion number affect branch . Patient verified history CVA stenting . Patient verified history active peptic ulcer upper gastrointestinal tract bleed Stenting . Patient show impaired renal function . ( serum creatinine concentration : &gt; 1.8 mg/dL ) Patient know contraindication aspirin clopidogrel . ( physician ass tolerability within range routine medical care ) Patient know disorder life expectancy le 12 month . Patient incompetent adhere clinical FUs list present protocol . 2 . Angiographic exclusion criterion : Lesions locate within saphenous venin graft ( SVG ) . Unprotected lesion leave coronary trunk . Lesions instent restenosis previously deploy DES BMS . Lesions anatomical structure coronary artery eligible treatment deployment Endeavor ZES .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Disease</keyword>
	<keyword>Vascular Disease</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
</DOC>